**Screened (n=242)**
- **Assigned to Study Treatment and Randomised (n=160)**
  - **CT327 0.05% w/w (n=40)**
    - Discontinuations (n=2; 5%)
      - Related to study drug: None (n=0)
      - Not related to study drug: Withdrew consent (n=2)
      - Completed n=38 (95%)
  - **CT327 0.15% w/w (n=40)**
    - Discontinuations (n=7; 17.5%)
      - Related to study drug: None (n=0)
      - Not related to study drug: Withdrew consent (n=4)
      - Lost to follow-up (n=3)
      - Completed n=33 (82.5%)
  - **CT327 0.5% w/w (n=40)**
    - Discontinuations (n=10; 25%)
      - Related to study drug: Lack of efficacy (n=5)
      - Adverse event (n=3)
      - Not related to study drug: Withdrew consent (n=1)
      - Protocol violation (n=1)
      - Completed n=30 (75%)
  - **Vehicle (n=40)**
    - Discontinuations (n=7; 17.5%)
      - Related to study drug: Lack of efficacy (n=1)
      - Adverse event (n=2)
      - Not related to study drug: Withdrew consent (n=2)
      - Compliance (n=1)
      - Lack of efficacy (n=1)
      - Completed n=33 (82.5%)

**Fig. S1.** Patient disposition. Discontinuations are from Baseline to Week 8. The first visit of the first patient was on 28/12/2011, and the last follow-up visit occurred on 17/9/2012.
Supplementary material to article by D. Roblin et al. “Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from In vitro and Tissue Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b, Randomised, Double-blind, Vehicle-controlled Clinical Trial in Patients with Psoriasis”